USE OF PSYCHOACTIVE DRUGS IN CHILDREN
by C. Lindsay DeVane and Khaja M. Ahsanuddin PSYCHOACTIVE DRUGS increasingly are being prescribed to pediatric patients. A review in Canada of a children's psychiatric unit showed that 65 percent of the patients received at least one of the following: chlorpromazine, diazepam, haloperidol, imipramine, or thioridazine. I Some problems confront prescribers and monitors of drug therapy in child psychiatry. These are highlighted in this brief commentary. By focusing on the prototype antidepressant imipramine, we can illustrate some issues that are common to the use of centrally active drugs in children.
The indications for imipramine that are approved by the Food and Drug Administration are limited to depressive illness in adults and childhood enuresis occurring beyond the age of six years. However, imipramine's efficacy has been proven in the treatment of C. LINDSAY a variety of childhood behavioral disorders.>:' These include childhood depression, encopresis, episodic anxiety (particularly when manifested as school phobia), and attention deficit disorder (hyperkinesis or minimum brain dysfunction). With the exception of childhood depression, these conditions have separate listings in the 1980 edition of the Diagnostic and Statistical Manual (DSM-III) of the American Psychiatric Association.
The diagnosis of depression in children has proven to be a complex issue because of extreme variability in the observed clinical picture. One group of children manifests most of the usually accepted elements of depression, such as the feeling of sadness, lowered selfesteem, and so on. A second group of children manifests aggressive, assaultive, or impulsive behavior that, at times, brings them into conflict with the law, behavior that clinicians have considered to be a part of childhood depression. A third group shows somatic complaints or phobic anxiety. The terms depressive equivalent and masked depression have been used to describe the symptoms of depression in children in the latter two groups. 5 Recent availability of reliable research instruments, such as the Children's Depression Inventory (CDI)6 and various structured interviews, has enhanced considerably the prospects for the development of a valid ,562
Drug Intelligence and Clinical Pharmacy VOL 17 profile of a depressed child. This also promises to improve the opportunities for research on the usefulness of antidepressants in children. Even while waiting for the depression that is occurring in children to be defined, one can only be impressed with the magnitude or scope of the problem when one notes the significant rate at which children and adolescents attempt suicide. These suicide attempts are not only increasing at an alarming rate, they are revealing depression to be a consistently significant underlying element. [7] [8] [9] Apart from diagnostic issues, there is a need for guidelines to dose and monitor response to imipramine and other antidepressants in children. There is considerable documentation of antidepressant pharmacokinetics in adults, but pharmacokinetic parameters derived from single-dose studies in children have not yet been reported in the literature. The available data are based on apparent steady-state plasma concentrations and their relationship to weight-adjusted doses. One report states that imipramine may be less avidly bound to plasma proteins in children, although the differences appear to be slight. 10 It was appropriately suggested that a greater susceptibility to side effects due to higher free drug concentrations may exist in children. Differences may exist between children and adults in tissue binding, volume of distribution, and other pharmacokinetic parameters.
An imipramine-related drug, clomipramine, has been reported to display age-dependent total body clearance." Children ages 5-10 years and adolescents ages 10-15 years had apparently faster drug elimination characteristics than did adults ages 20-25. A recent review of tricyclic antidepressant pharmacokinetics in children concluded that children's metabolic Clearance of imipramine is greater than that of adults. Children apparently demethylate imipramine more rapidly than adults; however, no difference exists between adults and children in the disposition of the demethylated metabolite desipramine.v':' Some hydroxylated metabolites of tricyclics recently have been recognized as pharmacologically active. Rapoport and Potter concluded that no difference exists between children and adults in the ability to hydroxylate tricyclics.!" However, there is a paucity of data on which to base these comparisons. Caution is warranted in applying adult pharmacokinetic data when establishing dosage guidelines for children.
Recommending children's doses from our knowledge of pharmacodynamic response in adults has certain limitations. In adults, imipramine's antidepressant effect is characterized by a slow onset of action with no apparent tolerance to efficacy from chronic dosing. This response pattern is mirrored in children. However, the response in both enuresis and hyperkinesis is characterized by a rapid onset of therapeutic effects and occasional tolerance with recrudescence of symptoms.v" Reports of imipramine plasma concentrations during treatment of prepubertal depression suggest that therapeutic efficacy is similar and that steady-state concentrations are at or below those seen for the antidepressant effect in adults.":" In other childhood disorders, limited data imply that therapeutic plasma concentrations are less than those required to treat adult depression optimally.v"
The literature shows that children have received generally higher mg/kg doses of imipramine than adults, frequently 5 mg/kg." The occurrence of electrocardiographic changes at this dosage suggests that doses should not exceed 3 mg/kg without some plasma concentration feedback to ensure safety. 19.20 There is discomfiting knowledge that the broad variability that exists in adult clearance of tricyclics is also present in children, reflected by widely ranging plasma concentrations from similarly administered mg/kg doses.
In this decade we are seeing the introduction of new antidepressants-second-generation drugs such as trazodone and bupropion, which have fewer anticholinergic and cardiovascular side effects in adults than do their older tricyclic counterparts; some of these agents are also less toxic when taken in overdoses. Given that tricyclic side effects in children are similar to those in adults, there will be a temptation to use these newer agents in children. Trazodone, for example, is not approved for use in persons under the age of 18. It is doubtful that the manufacturers of second-generation antidepressants will seek marketing approval for use in children until years after their drugs' place in adult psychiatry is firmly established and research and development costs have been recouped. This is lamentable. Safer drugs are needed for pediatric patients because the poisoning of children by tricyclics is a continuing story.
In summary, there are valid indications for the use of antidepressants and other psychoactive drugs in children. Drawbacks to the proper utilization of these drugs include the attitude of alarmists who believe that no medications should be used in children; the occasional unacceptabiIity, to parents, of pediatric drug use; the problems of compliance in the classroom setting; and, especially, the limited research in some areas of child psychiatry. These areas include pharmacodynamic and pharmacokinetic characterization of drugs, based on valid and replicated research diagnostic criteria. Certainly limitations exist, but pharmacotherapy in child psychiatry is useful and need not be avoided. Recently, however, I had an experience that left me wondering whether we have made any progress at all. I am referring to what may be the biggest, most frustrating setback of my professional career. I was asked to review the records of a patient accidentally overdosed with aspirin resulting from the sudden, unexpected release of the drug from a popular enteric-coated preparation. It seems that the tablets accumulated in the stomach of a middle-aged woman who had developed a gastric outlet obstruction. The release was precipitated by vigorous antacid therapy given for symptomatic relief of the obstruction, causing the coating to break down. The patient suffered severe salicylate intoxication. Although she survived the poisoning, she was left blind. The case was, in my opinion, a clear example of negligence on the part of her physicians.
The initial phase of my testimony was routine-the first thing to do was establish my qualifications as a drug expert. I had been through this before. There were questions about my schooling, my professional appointments, my current position. There were the usual .564
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